Different substitutions of imidazolones were synthesized and screened first for the in vitro anticancer activity at concentrations of 12.5 – 100 μg/ ml on Hela cell lines. Out of these eight synthesized compounds, the most active compound 3C-BRS was selected for in vivo anticancer activity using Ehrlich ascites carcinoma (EAC), using liquid tumor model. So 3CBRS was found be an effective anticancer agent.
|Number of pages||10|
|Publication status||Published - 30-08-2009|
All Science Journal Classification (ASJC) codes
- Drug Discovery